Published in Women's Health Weekly, September 15th, 2005
"A human papillomavirus (HPV) multiplexed competitive Luminex immunoassay first described by Opalka et al., was optimized and validated for use in epidemiology studies and vaccine clinical trials. Optimization increased both the analytical sensitivity and the clinical specificity of the assay to more effectively discriminate the low-titer antibody response of HPV-infected persons from noninfected individuals," investigators in the United States report.
"The characteristics of the assay that were optimized...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly